NEVVI Medicare utilization intelligence
or

← back

Provider profile

MCCARTHY, TIMOTHY M.D.

Hematology-Oncology · NPI 1881963403 · FAIRFAX, VA

1
Groups
67
Codes · 2024
76,486
Disclosed services

MCCARTHY, TIMOTHY is a Hematology-Oncology in FAIRFAX, VA, a member of 1 medical group, who billed 67 distinct codes to Medicare Part B in 2024.

Groups: VIRGINIA CANCER SPECIALISTS, P.C. (FAIRFAX, VA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

76,486
disclosed services
67
codes billed to Medicare Part B
Prior year · CY2023 70,164 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J9025 Injection, azacitidine, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J0897 Injection, denosumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J9041 Injection, bortezomib, 0.1 mg
80053 Blood test, comprehensive group of blood chemicals
J1100 Injection, dexamethasone sodium phosphate, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
82784 Gammaglobulin (immune system protein) measurement
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
83883 Nephelometry, test method using light
J1626 Injection, granisetron hydrochloride, 100 mcg
36415 Insertion of needle into vein for collection of blood sample
88185 Flow cytometry technique for dna or cell analysis, each additional marker
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
84165 Protein measurement, serum
86334 Immunologic analysis technique on serum (immunofixation)
82232 Beta-2 microglobulin (protein) level
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96413 Administration of chemotherapy into vein, 1 hour or less
96375 Injection of additional new drug or substance into vein
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
J3489 Injection, zoledronic acid, 1 mg
83615 Lactate dehydrogenase (enzyme) level
96372 Injection of drug or substance under skin or into muscle
84443 Blood test, thyroid stimulating hormone (tsh)
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
83010 Haptoglobin (serum protein) level
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
85046 Red blood count automated, with additional calculations
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J1200 Injection, diphenhydramine hcl, up to 50 mg
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
96417 Administration of additional new drug or substance into vein, 1 hour or less
82378 Carcinoembryonic antigen (cea) protein level
J3490 Unclassified drugs
82607 Cyanocobalamin (vitamin b-12) level
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
83735 Magnesium level
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
82746 Folic acid level, serum
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
85651 Red blood cell sedimentation rate, to detect inflammation, non-automated
96361 Infusion into a vein for hydration, each additional hour
96411 Administration of additional new drug or substance into vein using push technique
84439 Thyroxine (thyroid chemical), free
84153 Psa (prostate specific antigen) measurement, total
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
84436 Thyroxine (thyroid chemical), total
J7030 Infusion, normal saline solution , 1000 cc
81001 Manual urinalysis test with examination using microscope, automated
84480 Thyroid hormone, t3 measurement, total
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
96360 Infusion into a vein for hydration, 31-60 minutes
88184 Flow cytometry technique for dna or cell analysis, first marker
G0008 Administration of influenza virus vaccine

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.